Slide 1: 2026 Q2 Report
2026 Q2 Report July 10th, 2026
Slide 2: Disclaimer
Disclaimer THIS PERESNTATION AND ITS CONTENTS ARE CONFIDENTIAL AND ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION IS UNLAWFUL. T
Slide 3: Topics for today
❖ Commercial update ❖ US market positioning post FDA clearance Topics for ❖ Outlook and priorities today ❖ Financial update ❖ Respond to your questions
Slide 4: Key messages for today
Key messages for today Five ASTar instruments were shipped and installed during Q2 with 1 continued expansion of commercial pipeline Expanded US menu was launched following FDA clearance in 2 April with very positive customer reception US existing customers upgraded to the expanded menu, wider 3 pip
Slide 5: Q-linea revolutionising AST | Flagship ASTar platform designed to save lives
Q-linea revolutionising AST | Flagship ASTar platform designed to save lives Fully-automated, random 1st access platform Minutes hands-on time ~2 simple interface, load-and-go system ➢ Comprehensive menu ➢ High reproducibility ➢ High throughput with 12 Hours turn-around time samples in parallel ~6 s
Slide 6: A new standard of care | Critical patient testing moving to rapid AST
A new standard of care | Critical patient testing moving to rapid AST Current standard of care Emerging new standard of care Clinical value (~$1.5 billion global market1) ($600 – 900 million global opportunity1) of information Colony-based AST Positive Blood Culture AST Whole Blood AST ❖ 5 – 7m bloo
Slide 7: Commercial development | Pipeline expanding at each stage
Commercial development | Pipeline expanding at each stage In Evaluation and/or Contracted ASTars ASTars in Clinical Use ASTar tests (MSEK) Contracting process1 Evaluation New during 2026 Contracting , , , , , , Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q >80 decisions expected PO received and in
Slide 8: US push | Expanded FDA-cleared panel positions ASTar at the forefront
US push | Expanded FDA-cleared panel positions ASTar at the forefront ASTar BC G- FDA v2 menu versus alternative on-market solutions ❖ ASTar now with by far the most drug-bug combinations ❖ Strong messaging towards clinicians who are critical decision-makers ❖ Complements clear ASTar workflow advant
Slide 9: Global expansion | Significant activity building eastwards
Global expansion | Significant activity building eastwards ❖ Strong interest in rapid AST across E. Europe, Middle East and Asia ❖ GCC progress despite geopolitical events with Ministry of Health approvals in Saudi Arabia and Kuwait ❖ Multiple markets opened: four new distributors signed, half-dozen
Slide 10: GCC | Two Ministries of Health complete positive reviews of ASTar
GCC | Two Ministries of Health complete positive reviews of ASTar National Guard Hospital (Saudi Arabia) and Al Amiri Hospital (Kuwait) publish ASTar evaluations ❖ Successful evaluation with Ministry of National Guard Health Affairs resulted in NUPCO1 approval ❖ Triggers purchasing process for MNGHA
Slide 11: Short-term priorities | Pipeline conversion and runway extension
Short-term priorities | Pipeline conversion and runway extension Commercial ❖ Conversion drive for all customers: Q3 and Q4 ramp-up, “Verify & Adopt” program priorities ❖ Reduce cycle times: validations vs. evaluations, GPO contracting, LIS preparation, stewardship ❖ Support existing customers to in
Slide 12: Financial highlights | Q2 2026
Financial highlights | Q2 2026 ❖ Contracted ASTar end of period 24 instruments (12) ❖ Net sales 1.5 MSEK (0.5) ❖ No capital sales in the quarter ❖ Of which; sales from consumables 1.3 MSEK (0.5 MSEK), and roughly same level as in Q1 2026 ❖ Annualised consumable sales per average contracted instrumen
Slide 13: OPEX development | Run rate cost level under 11 MSEK per month
OPEX development | Run rate cost level under 11 MSEK per month ersonnel expenses ther external costs ❖ Reorganisation and office relocation programs ( thousand) completed during Q2 2026 ❖ OPEX outlook below 11 MSEK per month during H2 2026 ❖ Further operating efficiencies will offset planned investm
Slide 14: Key topics for Q-linea going forward financially
Key topics for Q-linea going forward financially Cost discipline ❖ Operating expenses below 11 MSEK per month ❖ Target investments in sales and market development funded through operational efficiencies Strong capital recovery ❖ Improve utilization of installed base → increase consumable revenue per
Slide 15: Thank you!
Thank Questions? you!